Isoquinolone Compounds as Subtype-Selective Agonists for Melatonin Receptors MT1 and MT2
Patent Information:
1. Filing Country: China
Application No: 200780050054.7
Filing Date: 17 July 2009
Patent No: ZL200780050054.7
Issue Date: 05 June 2013
2. Filing Country: USA
Application No: 12/523532
Filing Date: 17 July 2009
Patent No: 8389544
Issue Date: 05 March 2013
Inventor 1: Prof. Yung Hou, WONG
Inventor 2: Dr. Maurice Kwok Chung, HO
Inventor 3: Dr. Yueqing, HU
Inventor 4: Dr. David Charles, NEW
Inventor 5: . Xixin, HE
Inventor 6: Ms. Haihong, PANG

Melatonin has been implicated in the regulation of a number of physiological processes and, thus, has been used in the treatment of various biological disorders. It is widely used in the treatment of chronobiological disorders such as seasonal affective disorders (SAD), primary and secondary insomnia, and sleep disorders caused by blindness, shift work (Sack et al., 1992) and jet lag. Melatonin has also been linked to retinal physiology, blood pressure regulation, and in the regulation of the immune system, inflammation, and cancer and tumor growth. The invention relates to isoquinolone derivatives and their use as therapeutic agents. In particular, the invention relates to isoquinolone compounds that are capable of modulating melatonin receptors and to pharmaceutical compositions containing such compounds for treating disorders or pathological conditions associated with melatonin receptors in mammalian subjects.
Potential Application   Advantage
Potential drug candidate for treating jet-lag, seasonal affective disorders, insomnia, circadian-related disorders and may also covering other pathophysiological conditions such as inflammation, tumour growth and neurodegenerative diseases.   Malatonin is not sub-type specific and despite its modulatory effects on various effector systems, has a short biological half-life, poor oral bioavailability and exhibits ubiquitous action. The compounds of current invention are more potent and stable than melatonin since they also exhibit selectivity towards each melatonin receptor sub-type.
Patent documents are available at [], and can be viewed by inserting patent no., application no. or TTC code <TTC Code> into the corresponding field.
Contact information :
Ms Shirley Woo
(852) 2358 7918
HKUST R and D Corporation Ltd
(852) 2358 7917
Technology Transfer Center
香港九龍清水灣 香港科技大學